Latest publications

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. De Bruin-Weller MS, Serra-Baldrich E, Barbarot S, Grond S, Schuster C, Petto H et al. Dermatol Ther (Heidelb) 2022 May 11

Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma. Hermans MM, Breugem CC, Schappin R, Jonge Poerink E, Mendels EJ, Ragamin A et al. Acta Derm Venereol 2022 May 04

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Beck LA, Deleuran M, Bissonnette R, De Bruin-Weller M, Galus R, Nakahara T et al. Am J Clin Dermatol 2022 May 03

Estimating the Risk of Severe Peanut Allergy Using Clinical Background and IgE Sensitization Profiles. Datema MR, Lyons SA, Fernández-Rivas M, Ballmer-Weber B, Knulst AC, Asero R et al. Front Allergy 2021; 2:670789

Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort. Van Muijen ME, Thomas SE, Groenewoud HMM, Otero ME, Ossenkoppele PM, Njoo MD et al. Acta Derm Venereol 2022 May 16; 102:adv00712

Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study. Alexis A, De Bruin-Weller M, Weidinger S, Soong W, Barbarot S, Ionita I et al. Dermatol Ther (Heidelb) 2022 Mar; 12(3):771-785

Ocular surface disease is common in moderate-to-severe atopic dermatitis patients. Achten RE, Bakker DS, Van Luijk CM, Van der Wal M, De Graaf M, Van Wijk F et al. Clin Exp Allergy 2022 Mar 16

Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review. Vincken NLA, Balak DMW, Knulst AC, Welsing PMJ, Van Laar JM et al. Rheumatology (Oxford) 2022 Mar 14

The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry. Voorberg AN, Romeijn GLE, De Bruin-Weller MS, Schuttelaar MLA et al. Contact Dermatitis 2022 Mar 13

Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. El Sharouni MA, Scolyer RA, Van Gils CH, Ch'ng S, Nieweg OE, Pennington TE et al. Eur J Cancer 2022 May; 167:123-132

Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD). De Bruin-Weller M, Pink AE, Ferrucci SM, Patrizi A, Svensson A, Schuttelaar MLA et al. J Dermatolog Treat 2022 Mar 08:1-6

Proposal for a 6-step approach for differential diagnosis of neonatal erythroderma. Cuperus E, Bygum A, Boeckmann L, Bodemer C, Bolling MC, Caproni M et al. J Eur Acad Dermatol Venereol 2022 Mar 03

Low dietary adherence after a positive food challenge in food allergic adults. Versluis A, Le TM, Erp FCV, Blankestijn MA, Houben GF, Knulst AC et al. Clin Transl Allergy 2022 Feb; 12(2):e12119

Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. El Sharouni MA, Scolyer RA, Van Gils CH, Ch'ng S, Nieweg OE, Pennington TE et al. Eur J Cancer 2022 May; 167:133-141

The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15 mm in thickness). El Sharouni MA, Rawson RV, Sigurdsson V, Witkamp AJ, Van Gils CH, Scolyer RA et al. J Am Acad Dermatol 2022 Feb 01